

REMARKS

By this amendment, Claims 79, 90 and 91 have been canceled without prejudice or disclaimer, Claims 41, 88 and 92-93 have been amended, and new Claims 94-185 have been added. Applicant maintains that the amendments do not raise an issue of new matter. Support for the amendment to Claim 41 can be found at least in Claim 79. Support for the amendment to Claim 88 can be found at least in Claim 90. Support the amendments to Claims 92 and 93 can be found at least in the previous version of the claims. Support for new Claims 94-171 can be found in the application as originally filed at least on page 7, bottom paragraph, and page 14, next to last paragraph. Support for new Claims 171-183 can be found in the application as originally filed at least on page 7, lines 17-18. Support for new Claims 184-185 can be found in the application as originally filed at least on page 17, Example 2. Entry of the amendments is respectfully requested.

Allowable Subject Matter

The claims have herein above been amended to be limited to the combination of pipamperone and citalopram in specified doses, which the Examiner has indicated are allowable.

Supplemental Information Disclosure Statement

This Supplemental Information Disclosure Statement (SIDS) is being submitted pursuant to 37 C.F.R. §1.97(b)(4) to make of record in the present application an Office Action issued on April 14, 2010 in patent family member U.S. patent Application No. 10/580, 962.

Applicant: Erik Buntinx
Serial No.: 10/725,965
Filed: December 2, 2003
page 16 of 16

CONCLUSIONS

In view of the amendments made hereinabove, the claims are understood to be in condition for allowance. If there is any minor matter preventing the allowance of the subject application, the Examiner is requested to telephone the undersigned attorney.

The Patent Office is hereby authorized to charge Deposit Account No. 01-1785 for the fees in filing claims in addition to the 46 claims previously paid for. No other fee is deemed necessary in connection with the filing of this reply. However, if any fee is required with this reply or to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785. Overpayments may also be credited to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: May 28, 2010
New York, New York

By /Alan D. Miller/
Alan D. Miller, Reg. No. 42,889